Abstract
We used the ELISA to measure the concentration of amyloid protein precursor with Kunitz type trypsin inhibitor domains (APPI) in CSF of dementia of the Alzheimer type (DAT) and examined the correlation of APPI with acetylcholinesterase (AChE) and somatostatin (SRIF). We found the APPI concentration in CSF of DAT to be significantly elevated compared with that of multi-infarct dementia and controls. We could significantly correlate APPI with AChE, but not correlate APPI with SRIF. The present results suggest that measurement of CSF APPI levels may be useful for diagnosis of DAT and the change of APPI may closely be associated with abnormality of acetylcholine system in DAT that has been reported.
MeSH terms
-
Acetylcholinesterase / biosynthesis*
-
Acetylcholinesterase / isolation & purification
-
Acetylcholinesterase / metabolism
-
Aged
-
Alzheimer Disease / cerebrospinal fluid*
-
Alzheimer Disease / physiopathology
-
Amyloid beta-Peptides / biosynthesis*
-
Amyloid beta-Peptides / metabolism
-
Amyloid beta-Peptides / pharmacokinetics
-
Aprotinin / biosynthesis*
-
Aprotinin / metabolism
-
Aprotinin / pharmacokinetics
-
Brain / metabolism
-
Electroencephalography
-
Female
-
Humans
-
Immunoblotting
-
Intelligence Tests
-
Male
-
Neurotransmitter Agents / metabolism
-
Protease Inhibitors / immunology
-
Protease Inhibitors / metabolism
-
Somatostatin / cerebrospinal fluid
-
Spectrophotometry
Substances
-
Amyloid beta-Peptides
-
Neurotransmitter Agents
-
Protease Inhibitors
-
Somatostatin
-
Aprotinin
-
Acetylcholinesterase